drugset
drugset / Trial / NCT00175864

Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.

NCT00175864 ↗

Phase 3 Withdrawn UCB Pharma
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a safety and efficacy study of add on therapy with seletracetam in patients experiencing refractory epilepsy.

Timeline

Start
2006-02
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Seletracetam Small molecule 160 mg Oral

Indications

epilepsy